MARKET

EPIX

EPIX

ESSA Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.52
+0.04
+0.62%
Closed 16:00 10/20 EDT
OPEN
6.60
PREV CLOSE
6.48
HIGH
6.76
LOW
6.51
VOLUME
38.78K
TURNOVER
--
52 WEEK HIGH
8.31
52 WEEK LOW
3.000
MARKET CAP
189.14M
P/E (TTM)
-6.6755
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific Symposia
HOUSTON, Texas and VANCOUVER, BC, Oct. 19, 2020 /CNW/ - ESSA Pharma Inc.
CNW Group · 1d ago
Government of Canada signs agreement for COVID-19 rapid tests and analyzers
GATINEAU, QC, Sept. 29, 2020 /CNW/ - The Government of Canada is protecting the health and safety of all Canadians, while moving quickly to have access to a safe and sustainable economic recovery.
CNW Group · 09/29 18:08
ESSA Pharma to Participate in Oppenheimer Fall Healthcare Life Science & MedTech Summit
HOUSTON and VANCOUVER, BC, Sept. 21, 2020 /CNW/ - ESSA Pharma Inc.
CNW Group · 09/21 12:00
ESSA Pharma Announces the Presentation of Additional Preclinical Data for EPI-7386 at the ESMO Virtual Congress 2020
HOUSTON and VANCOUVER, BC, Sept. 17, 2020 /CNW/ - ESSA Pharma Inc.
CNW Group · 09/17 21:05
ESSA Pharma Announces Fast Track Designation Granted by the FDA to EPI-7386 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
HOUSTON and VANCOUVER, BC, Sept. 14, 2020 /CNW/ - ESSA Pharma Inc.
CNW Group · 09/14 12:00
ESSA Pharma to Participate in Multiple Upcoming Investor Conferences
ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI; ) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the H.C. Wainwright 22nd Annual Global Investment
PR Newswire · 09/10 12:00
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Sarepta Flags Potential Delay In Gene Therapy Trial
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9)
Benzinga · 09/10 11:20
ESSA's Novel Prostate Cancer Treatment In Clinical Trial: Pfizer Is New Lead Investor
ESSA's EPI-7386 novel approach to treat prostate cancer by targeting the N-terminal domain androgen receptor inhibitor is now in Phase 1 trials. The first patient was dosed on July 15.EPI-7386 is far more potent than 1st generation EPI-506 with significantly improved potency, stability and much longer 24-hr predicted half-life. Pre-clinical anti-tumor effect impressive, especially in combo with ENZ.Patent protection for EPI-7386 anticipated in 2040.On July 31st, ESSA closed a public offering of common shares for gross proceeds of US$48,990,000 with Pfizer as Lead Investor with right of first access to certain clinical data.If Phase 1a/1b EPI-7386 clinical studies go well, including combination studies, ESSA could be a takeover target in 2022.
Seekingalpha · 08/19 15:48
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EPIX. Analyze the recent business situations of ESSA Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EPIX stock price target is 11.17 with a high estimate of 16.50 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 29
Institutional Holdings: 17.63M
% Owned: 60.77%
Shares Outstanding: 29.01M
TypeInstitutionsShares
Increased
4
208.81K
New
7
342.41K
Decreased
4
739.25K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.98%
Pharmaceuticals & Medical Research
-0.26%
Key Executives
Chairman/Director
Richard Glickman
President/Chief Executive Officer/Director
David Parkinson
Chief Financial Officer/Primary Contact
David Wood
Chief Operating Officer/Executive Vice President
Peter Virsik
Chief Technology Officer/Director
Raymond Andersen
Chief Scientific Officer/Director
Marianne Sadar
Other
Frank Perabo
Director
Franklin Berger
Director
Ari Brettman
Director
Scott Requadt
Director
Gary Sollis
Director
Otello Stampacchia
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About EPIX
ESSA Pharma, Inc. is a Canada-based pharmaceutical company. The Company is focused on developing therapies for the treatment of castration-resistant prostate cancer (CRPC). It is developing EPI-7386 for the treatment of metastatic CRPC (mCRPC). It is also developing EPI-7386 combination therapy for mCRPC. In addition to this, the Company's pipeline also includes antien for triple negative androgen receptor (AR+) breast cancer. Its aniten compounds bind to the N-terminal domain of the androgen receptor (AR), inhibiting AR driven transcription and the AR signaling pathway in a manner which bypasses the drug resistance mechanisms associated with current anti-androgens.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of ESSA Pharma Inc stock information, including NASDAQ:EPIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EPIX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EPIX stock methods without spending real money on the virtual paper trading platform.